| Literature DB >> 28874821 |
Marja A Heiskanen1, Tanja J Sjöros1, Ilkka H A Heinonen1,2, Eliisa Löyttyniemi3, Mikko Koivumäki1, Kumail K Motiani1, Jari-Joonas Eskelinen1, Kirsi A Virtanen1, Juhani Knuuti1,2, Jarna C Hannukainen1, Kari K Kalliokoski4.
Abstract
Type 2 diabetes mellitus (T2DM) is associated with reduced myocardial glucose uptake (GU) and increased free fatty acid uptake (FFAU). Sprint interval training (SIT) improves physical exercise capacity and metabolic biomarkers, but effects of SIT on cardiac function and energy substrate metabolism in diabetic subjects are unknown. We tested the hypothesis that SIT is more effective than moderate-intensity continuous training (MICT) on adaptations in left and right ventricle (LV and RV) glucose and fatty acid metabolism in diabetic subjects. Twenty-six untrained men and women with T2DM or prediabetes were randomized into two-week-long SIT (n = 13) and MICT (n = 13) interventions. Insulin-stimulated myocardial GU and fasted state FFAU were measured by positron emission tomography and changes in LV and RV structure and function by cardiac magnetic resonance. In contrast to our hypothesis, SIT significantly decreased GU compared to MICT in LV. FFAU of both ventricles remained unchanged by training. RV end-diastolic volume (EDV) and RV mass increased only after MICT, whereas LV EDV, LV mass, and RV and LV end-systolic volumes increased similarly after both training modes. As SIT decreases myocardial insulin-stimulated GU compared to MICT which may already be reduced in T2DM, SIT may be metabolically less beneficial than MICT for a diabetic heart.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28874821 PMCID: PMC5585392 DOI: 10.1038/s41598-017-10931-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study design. OGTT, oral glucose tolerance test; VO2peak, peak oxygen uptake; CMR, cardiac magnetic resonance; FTHA-PET, positron emission tomography study for myocardial fat metabolism; FDG-PET, positron emission tomography study for myocardial glucose metabolism.
Numbers of completed and uncompleted experiments in the study.
| SIT | MICT | |||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| Number of subjects who participated at least in one measurement | 13 | 11 | 13 | 10 |
| Myocardial GU, completed | 11* | 9 | 13 | 10 |
| Missing because | ||||
| - discontinued intervention | 1† | 2 | — | 3 |
| - technical problem in clamp | 1 | — | — | — |
| - physiological problem | — | 1‡ | — | — |
| - PRE-measurement was not done | — | 1 | — | — |
| Myocardial FFAU, completed | 12 | 8 | 13 | 9 |
| Missing because | ||||
| - discontinued intervention | — | 2 | — | 3 |
| - technical problem in tracer production | 1 | 2 | — | 1 |
| - PRE-measurement was not done | — | 1 | — | — |
| Basal perfusion, completed | 13 | 10 | 13 | 10 |
| Missing because | ||||
| - discontinued intervention | — | 2 | — | 3 |
| - technical problem in tracer production or PET scanning | — | 1 | — | — |
| Adenosine-stimulated perfusion, completed | 11 | 9 | 13 | 10 |
| Missing because | ||||
| - discontinued intervention | — | 2 | — | 3 |
| - physiological problem | 2§ | 2§ | — | — |
| CMR, completed | 12 | 11 | 13 | 10 |
| Missing because | ||||
| - discontinued intervention | — | 2 | — | 3 |
| - physiological problem | 1† | — | — | — |
SIT, sprint interval training; MICT, moderate-intensity continuous training; GU, glucose uptake; FFAU, free fatty acid uptake; CMR, cardiac magnetic resonance imaging.
*For RV GU, number of analysed subjects was 10 due to poor visibility of the RV free wall in one subject.
†Subject experienced claustrophobic feelings during CMR scan and dropped out from the trial after the first measurement day.
‡Problem in the cannulation.
§Two subjects had a history of asthma.
Subject characteristics and whole-body responses to SIT and MICT.
| SIT | MICT |
| |||||
|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Group | Time | Group x Time | |
|
| 13 | 11 | 13 | 10 | |||
| men/women, | 9/4 | 7/4 | 7/6 | 6/4 | 0.688* | ||
| T2DM/prediabetes, | 11/2 | 10/1 | 6/7 | 4/6 | 0.097* | ||
| At least one glucose lowering medication, | 9 | 4 | 0.115* | ||||
| Metformin | 7 | 4 | 0.428* | ||||
| DPP-4 inhibitors (sitagliptin) | 4 | 1 | 0.322* | ||||
| Sulfonylurea (glimepiride) | 1 | 0.999* | |||||
| Other medication, | |||||||
| Antihypertensives | 5 | 6 | 0.999* | ||||
| Statins | 4 | 3 | 0.999* | ||||
| Affective medication | 3 | 0.220* | |||||
| Menopausal hormone therapy | 1 | 2 | 0.999* | ||||
| Age, yr | 49 (47, 51) | 49 (46, 51) | 0.849† | ||||
| Height, cm | 173 (168, 179) | 172 (167, 176) | 0.614† | ||||
| Weight, kg | 88.9 (80.6, 97.2) | 88.4 (80.1, 96.7) | 91.5 (84.5, 98.6) | 91.1 (84.0, 98.1) | 0.620 | 0.083 | 0.952 |
| BSA, m2 | 2.0 (1.9, 2.1) | 2.0 (1.9, 2.1) | 2.0 (2.0, 2.1) | 2.0 (1.9, 2.1) | 0.543 | 0.131 | 0.877 |
| BMI | 30.5 (28.5, 32.5) | 30.3 (28.4, 32.3) | 31.0 (29.4, 32.7) | 30.8 (29.2, 32.5) | 0.688 | 0.070 | 0.833 |
| Fat, % | 34.8 (31.4, 38.5) | 33.8 (30.5, 37.5) | 33.8 (30.8, 36.9) | 32.9 (30.0, 36.0) | 0.666 |
| 0.872 |
| FFM, kg | 57.0 (51.8, 62.2) | 57.6 (52.4, 62.8) | 59.6 (55.0, 64.2) | 59.8 (55.2, 64.5) | 0.492 | 0.109 | 0.541 |
| VO2peak, ml·kg−1·min−1 | 25.7 (23.2, 28.2) | 27.0 (24.6, 29.5)‡ | 27.0 (24.9, 29.2) | 26.9 (24.6, 29.1)§ | 0.716 | 0.123 |
|
| M-value, µmol·kg−1·min−1 | 20.6 (13.4, 27.7) | 25.7 (18.4, 33.0) | 15.7 (9.7, 21.6) | 19.7 (13.6, 25.8) | 0.237 |
| 0.657 |
| HbA1c, % | 5.7 (5.4, 6.0) | 5.5 (5.2, 5.8) | 5.8 (5.5, 6.0) | 5.6 (5.3, 5.9) | 0.704 |
| 0.844 |
| HbA1c, mmol/mol | 38.7 (35.5, 42.0) | 36.9 (33.6, 40.2) | 39.6 (36.9, 42.4) | 37.6 (34.7, 40.5) | 0.701 |
| 0.816 |
| Fasting glucose, mmol/l | 7.1 (6.5, 7.7) | 7.0 (6.4, 7.6) | 6.8 (6.3, 7.3) | 7.0 (6.4, 7.5) | 0.715 | 0.953 | 0.395 |
| OGTT 2 h glucose, mmol/l | 10.4 (8.6, 12.3) | 9.1 (7.2, 11.1) | 10.5 (8.9, 12.1) | 10.3 (8.6, 12.0) | 0.604 | 0.089 | 0.207 |
| Fasting insulin, pmol/l | 11.5 (7.8, 17.0) | 11.6 (7.8, 17.2) | 13.2 (9.5, 18.5) | 13.5 (9.5, 19.0) | 0.565 | 0.881 | 0.933 |
| OGTT 2 h insulin, pmol/l | 75.0 (50.3, 111.7) | 71.1 (46.6, 108.4) | 68.1 (48.1, 96.3) | 62.9 (42.7, 92.5) | 0.654 | 0.615 | 0.921 |
| Glucose AUC in OGTT | 1274 (1142, 1407) | 1242 (1104, 1379) | 1298 (1184, 1412) | 1323 (1200, 1446) | 0.527 | 0.905 | 0.413 |
| Insulin AUC in OGTT | 7162 (5264, 9746) | 7109 (5181, 9756) | 6871 (5273, 8954) | 6748 (5106, 8920) | 0.810 | 0.849 | 0.937 |
The results are presented as means (95% CI) for age and height. For all other parameters the results are presented as model-based means (95% CI). Results have been reported previously by Sjöros et al.[34]. Group p-value indicates whether there is a level difference between the groups, time p-value displays the mean change between pre- and post-measurements and group x time p-value indicates whether the mean changes are different between the groups. SIT, sprint interval training; MICT, moderate-intensity continuous training; n, number of subjects; T2DM, type 2 diabetes mellitus; BSA, body surface area; FFM, fat free mass; AUC, area under curve; *Fisher’s exact test at baseline; †T-test; ‡SIT time effect, p = 0.013; §MICT time effect, p = 0.75. Significant differences are printed in boldface.
Myocardial metabolism and plasma concentrations during the PET studies and myocardial blood flow before and after SIT and MICT.
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
| |||||||
|
| |||||||
| LV GU*, µmol·100 g−1·min−1 | 42 (35, 48) | 36 (29, 43) | 37 (32, 43) | 41 (35, 47) | 0.956 | 0.541 |
|
| RV GU*, µmol·100 g−1·min−1 | 10.5 (7.6, 13.4) | 9.4 (6.4, 12.4) | 8.0 (5.7, 10.2) | 8.7 (6.4, 11.0) | 0.362 | 0.792 | 0.125 |
|
| |||||||
| Glucose, mmol/l | 4.7 (4.5, 4.9) | 4.9 (4.7, 5.2) | 5.0 (4.8, 5.2) | 5.0 (4.8, 5.2) | 0.117 | 0.122 | 0.241 |
| FFA, mmol/l | 0.09 (0.06, 0.11) | 0.07 (0.05, 0.10) | 0.09 (0.06, 0.11) | 0.08 (0.05, 0.10) | 0.931 | 0.126 | 0.902 |
| Insulin, pmol/l | 88.9 (80.3, 97.4) | 90.4 (80.9, 99.8) | 86.0 (78.8, 93.2) | 85.8 (77.7, 94.0) | 0.463 | 0.837 | 0.798 |
|
| |||||||
|
| |||||||
| LV FFAU, µmol·100 g−1·min−1 | 5.4 (4.4, 6.4) | 5.7 (4.5, 6.8) | 5.4 (4.6, 6.3) | 5.2 (4.2, 6.2) | 0.756 | 0.952 | 0.510 |
| RV FFAU, µmol·100 g−1·min−1 | 2.0 (1.6, 2.4) | 2.2 (1.8, 2.6) | 2.2 (1.9, 2.5) | 2.1 (1.7, 2.4) | 0.935 | 0.750 | 0.248 |
|
| |||||||
| Glucose, mmol/l | 6.1 (5.6, 6.7) | 5.9 (5.3, 6.5) | 6.0 (5.5, 6.4) | 5.9 (5.4, 6.4) | 0.796 | 0.095 | 0.474 |
| FFA, mmol/l | 0.89 (0.77, 1.01) | 0.87 (0.74, 1.01) | 0.89 (0.79, 0.99) | 0.86 (0.75, 0.97) | 0.927 | 0.499 | 0.828 |
| Insulin, pmol/l | 10.8 (6.9, 14.6) | 8.3 (4.3, 12.2) | 10.4 (7.2, 13.5) | 8.6 (5.3, 11.9) | 0.993 |
| 0.539 |
|
| |||||||
| Basal LV perfusion, ml·g−1·min−1 | 1.1 (1.0, 1.3) | 1.2 (1.0, 1.4) | 1.1 (1.0, 1.3) | 1.1 (0.9, 1.2) | 0.544 | 0.765 | 0.173 |
| Adenosine-stimulated LV perfusion, ml·g−1·min−1 | 3.7 (3.0, 4.4) | 3.9 (3.1, 4.7) | 4.4 (3.8, 5.0) | 4.7 (4.0, 5.4) | 0.075 | 0.355 | 0.884 |
| LV perfusion reserve | 3.3 (2.6, 4.1) | 3.4 (2.6, 4.2) | 3.8 (3.2, 4.4) | 4.4 (3.7, 5.1) | 0.092 | 0.201 | 0.276 |
| Basal coronary resistance, mm Hg·ml·g−1·min−1 | 93 (78, 108) | 83 (67, 98) | 99 (86, 112) | 99 (85, 112) | 0.244 | 0.161 | 0.192 |
| Adenosine-stimulated coronary resistance, mm Hg·ml·g−1·min−1 | 26 (21, 32) | 23 (18, 28) | 25 (21, 29) | 20 (16, 25) | 0.407 | 0.055 | 0.775 |
The results are presented as model-based means (95% CI). Group p-value indicates whether there is a level difference between the groups, time p-value displays the mean change between pre- and post-measurements and group x time p-value indicates whether the mean changes are different between groups. SIT, sprint interval training; MICT, moderate-intensity continuous training; FDG, 2-deoxy-2-(18 F)fluoro-D-glucose; FTHA, 14(R,S)-[18 F]fluoro-6-thia-heptadecanoic acid; LV, left ventricle; RV, right ventricle; GU, glucose uptake; FFA, plasma free fatty acid concentration; FFAU, free fatty acid uptake. *Adjusted for plasma FFA concentration during the FDG-PET study. The FTHA-PET study was conducted in the fasting state and the FDG-PET study under hyperinsulinemic euglycemic clamp. Significant differences are printed in boldface.
Cardiac dimensions and function and hemodynamic parameters before and after SIT and MICT.
| SIT | MICT |
| |||||
|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Group | Time | Group x Time | |
|
| |||||||
| LV mass, g | 100 (86, 113) | 101 (87, 115) | 120 (109, 132) | 122 (111, 134) |
|
| 0.813 |
| LV mass/BSA, g/m2 | 49 (44, 54) | 50 (45, 55) | 59 (55, 63) | 60 (56, 64) |
|
| 0.809 |
| LV EDV, ml | 135 (115, 155) | 140 (120, 160) | 156 (139, 173) | 166 (149, 183) | 0.076 |
| 0.153 |
| LV EDV/BSA, ml/m2 | 67 (60, 73) | 69 (63, 76) | 76 (71, 82) | 81 (76, 87) |
|
| 0.168 |
| LV ESV, ml | 48 (36, 60) | 53 (41, 65) | 56 (46, 66) | 62 (51, 72) | 0.276 |
| 0.952 |
| LV ESV/BSA, ml/m2 | 24 (19, 28) | 26 (21, 31) | 27 (23, 31) | 30 (26, 34) | 0.210 |
| 0.958 |
| LV SV, ml | 87 (75, 98) | 86 (75, 98) | 100 (90, 109) | 104 (94, 114) |
| 0.147 | 0.054 |
| LV SV/BSA, ml/m2 | 43 (39, 47) | 43 (39, 47) | 49 (46, 52) | 51 (48, 54) |
| 0.095 |
|
| LV CO, l·min−1 | 6.3 (5.6, 7.0) | 6.0 (5.2, 6.7) | 6.8 (6.2, 7.4) | 6.6 (5.9, 7.2) | 0.215 | 0.108 | 0.663 |
| LV CO/BSA, l·min−1/m2 | 3.2 (2.9, 3.5) | 3.0 (2.6, 3.3) | 3.2 (2.9, 3.5) | 3.2 (2.9, 3.5) | 0.490 | 0.331 | 0.223 |
| LV EF, % | 65 (62, 69) | 63 (59, 67) | 64 (61, 68) | 63 (60, 67) | 0.925 | 0.068 | 0.466 |
|
| |||||||
| RV mass, g | 24.8 (21.8, 27.8) | 24.8 (21.8, 27.8) | 27.5 (25, 30) | 29.3 (26.7, 31.8) | 0.069 |
|
|
| RV mass/BSA, g/m2 | 12.3 (11.4, 13.2) | 12.3 (11.4, 13.3) | 13.4 (12.7, 14.2) | 14.3 (13.5, 15.1) |
|
|
|
| RV EDV, ml | 145 (126, 165) | 147 (128, 167) | 167 (151, 184) | 182 (165, 199) |
|
|
|
| RV EDV/BSA, ml/m2 | 72 (66, 78) | 74 (67, 80) | 82 (76, 87) | 89 (83, 95) |
|
|
|
| RV ESV, ml | 59 (46, 72) | 61 (48, 74) | 69 (58, 79) | 79 (68, 90) | 0.092 |
| 0.120 |
| RV ESV/BSA, ml/m2 | 29 (24, 34) | 31 (25, 36) | 33 (29, 38) | 39 (34, 43) | 0.069 |
| 0.149 |
| RV SV, ml | 86 (76, 97) | 86 (75, 97) | 99 (90, 108) | 103 (93, 112) |
| 0.138 | 0.094 |
| RV SV/BSA, ml/m2 | 43 (39, 47) | 43 (39, 47) | 48 (45, 51) | 50 (47, 53) |
| 0.078 | 0.080 |
| RV CO, l·min-−1 | 6.2 (5.6, 6.9) | 5.9 (5.3, 6.6) | 6.7 (6.2, 7.3) | 6.4 (5.8, 7.1) | 0.250 | 0.077 | 0.965 |
| RV CO/BSA, l·min−1/m2 | 3.1 (2.8, 3.4) | 3.0 (2.7, 3.3) | 3.2 (2.9, 3.4) | 3.2 (2.9, 3.5) | 0.500 | 0.321 | 0.249 |
| RV EF, % | 60 (56, 64) | 58 (54, 63) | 60 (56, 63) | 57 (53, 61) | 0.721 |
| 0.688 |
|
| |||||||
| HRrest, beats/min | 73 (68, 78) | 70 (65, 75) | 69 (64, 73) | 64 (59, 68) | 0.076 |
| 0.376 |
| BPsyst, mm Hg | 135 (129, 142) | 133 (126, 140) | 146 (141, 152) | 139 (133, 145) |
|
| 0.192 |
| BPdiast, mm Hg | 86 (81, 90) | 82 (77, 87) | 89 (85, 93) | 82 (77, 86) | 0.652 |
| 0.354 |
| BPmap, mm Hg | 102 (97, 107) | 99 (93, 104) | 108 (104, 112) | 101 (96, 105) | 0.194 |
| 0.269 |
| RPP, mm Hg·min−1 | 9855 (9073, 10637) | 9334 (8509, 10158) | 10008 (9328, 10687) | 8854 (8079, 9630) | 0.736 |
| 0.211 |
| LV work, mm Hg ·l·min−1 | 643 (558, 729) | 587 (499, 675) | 733 (660, 806) | 662 (580, 743) | 0.129 |
| 0.760 |
| LV work index, mm Hg ·l·min−1·g−1 | 6.6 (5.9, 7.4) | 6.0 (5.2, 6.8) | 6.2 (5.6, 6.9) | 5.6 (4.9, 6.3) | 0.342 |
| 0.941 |
The results are presented as model-based means (95% CI). Group p-value indicates whether there is a level difference between the groups, time p-value displays the mean change between pre- and post-measurements and group x time p-value indicates whether the mean changes are different between groups. SIT, sprint interval training; MICT, moderate-intensity continuous training; LV, left ventricle; RV, right ventricle; BSA, body surface area; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; CO, cardiac output; EF, ejection fraction; HRrest, heart rate at rest; BPsyst, systolic blood pressure; BPdiast, diastolic blood pressure; BPmap, mean arterial pressure; RPP, rate pressure product (calculated as HRrest·BPsyst). The hemodynamic parameters describe the mean values of the screening day (included only in the pre-intervention values) and the two PET study days before and after the intervention. Significant differences are printed in boldface.